| ALK (2p23.2) / ROS1 (6q22.1) | C10orf10 (10q11.21) / ROS1 (6q22.1) | CCDC6 (10q21.2) / ROS1 (6q22.1) |
|
CD74 (5q32) / ROS1 (6q22.1) | CD74 (5q33.1) / ROS1 (6q22.1) | CEP85L (6q22.31) / ROS1 (6q22.1) |
|
CLIP1 (12q24.31) / ROS1 (6q22.1) | CLTC (17q23.1) / ROS1 (6q22.1) | ERC1 (12p13.33) / ROS1 (6q22.1) |
|
EZR (6q25.3) / ROS1 (6q22.1) | GOPC (6q22.1) / ROS1 (6q22.1) | HLA-A (6p22.1) / ROS1 (6q22.1) |
|
KDELR2 (7p22.1) / ROS1 (6q22.1) | KMT2A (11q23.3) / ROS1 (6q22.1) | LRIG3 (12q14.1) / ROS1 (6q22.1) |
|
MYO5A (15q21.2) / ROS1 (6q22.1) | PPFIBP1 (12p11.23) / ROS1 (6q22.1) | PWWP2A (5q33.3) / ROS1 (6q22.1) |
|
ROS1 (6q22.1) / CCDC6 (10q21.2) | ROS1 (6q22.1) / CD74 (5q32) | ROS1 (6q22.1) / CD74 (5q33.1) |
|
ROS1 (6q22.1) / EZR (6q25.3) | ROS1 (6q22.1) / GOPC (6q22.1) | ROS1 (6q22.1) / LRIG3 (12q14.1) |
|
ROS1 (6q22.1) / SDC4 (20q13.12) | ROS1 (6q22.1) / SLC34A2 (4p15.2) | SDC4 (20q13.12) / ROS1 (6q22.1) |
|
SHTN1 (10q25.3) / ROS1 (6q22.1) | SLC34A2 (4p15.2) / ROS1 (6q22.1) | TFG (3q12.2) / ROS1 (6q22.1) |
|
TPM3 (1q21.3) / ROS1 (6q22.1) | YWHAE (17p13.3) / ROS1 (6q22.1) | ZCCHC8 (12q24.31) / ROS1 (6q22.1) |
|
Mitelman Database of Chromosome Aberrations and Gene Fusions in Cancer |
Mitelman F Johansson B and Mertens F |
http://cgap.nci.nih.gov/Chromosomes/Mitelman |
|
ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers |
Aisner DL, Nguyen TT, Paskulin DD, Le AT, Haney J, Schulte N, Chionh F, Hardingham J, Mariadason J, Tebbutt N, Doebele RC, Weickhardt AJ, Varella-Garcia M |
Mol Cancer Res 2014 Jan;12(1):111-8 |
PMID 24296758 |
|
Acquired resistance to crizotinib from a mutation in CD74-ROS1 |
Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S, Wilner KD, Lockerman EL, Khan TM, Mahmood S, Gainor JF, Digumarthy SR, Stone JR, Mino-Kenudson M, Christensen JG, Iafrate AJ, Engelman JA, Shaw AT |
N Engl J Med 2013 Jun 20;368(25):2395-401 |
PMID 23724914 |
|
ROS1 rearrangements define a unique molecular class of lung cancers |
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R, Mark EJ, Batten JM, Chen H, Wilner KD, Kwak EL, Clark JW, Carbone DP, Ji H, Engelman JA, Mino-Kenudson M, Pao W, Iafrate AJ |
J Clin Oncol 2012 Mar 10;30(8):863-70 |
PMID 22215748 |
|
Fusion of FIG to the receptor tyrosine kinase ROS in a glioblastoma with an interstitial del(6)(q21q21) |
Charest A, Lane K, McMahon K, Park J, Preisinger E, Conroy H, Housman D |
Genes Chromosomes Cancer 2003 May;37(1):58-71 |
PMID 12661006 |
|
ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice |
Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D |
Cancer Res 2006 Aug 1;66(15):7473-81 |
PMID 16885344 |
|
Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer |
Chin LP, Soo RA, Soong R, Ou SH |
J Thorac Oncol 2012 Nov;7(11):1625-30 |
PMID 23070242 |
|
Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia |
Cilloni D, Carturan S, Bracco E, Campia V, Rosso V, Torti D, Calabrese C, Gaidano V, Niparuck P, Favole A, Signorino E, Iacobucci I, Morano A, De Luca L, Musto P, Frassoni F, Saglio G |
Leuk Res 2013 May;37(5):520-30 |
PMID 23415111 |
|
Foretinib is a potent inhibitor of oncogenic ROS1 fusion proteins |
Davare MA, Saborowski A, Eide CA, Tognon C, Smith RL, Elferich J, Agarwal A, Tyner JW, Shinde UP, Lowe SW, Druker BJ |
Proc Natl Acad Sci U S A 2013 Nov 26;110(48):19519-24 |
PMID 24218589 |
|
Molecular pathways: ROS1 fusion proteins in cancer |
Davies KD, Doebele RC |
Clin Cancer Res 2013 Aug 1;19(15):4040-5 |
PMID 23719267 |
|
Identifying and targeting ROS1 gene fusions in non-small cell lung cancer |
Davies KD, Le AT, Theodoro MF, Skokan MC, Aisner DL, Berge EM, Terracciano LM, Cappuzzo F, Incarbone M, Roncalli M, Alloisio M, Santoro A, Camidge DR, Varella-Garcia M, Doebele RC |
Clin Cancer Res 2012 Sep 1;18(17):4570-9 |
PMID 22919003 |
|
Novel targets in non-small cell lung cancer: ROS1 and RET fusions |
Gainor JF, Shaw AT |
Oncologist 2013;18(7):865-75 |
PMID 23814043 |
|
Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm |
Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, Heo DS, Bang YJ, Chung DH |
J Thorac Oncol 2013 Nov;8(11):1445-50 |
PMID 24128715 |
|
Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma |
Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, Wang Y, Deng G, Zhu L, Tan Z, Hu Y, Wu C, Nardone J, MacNeill J, Ren J, Reeves C, Innocenti G, Norris B, Yuan J, Yu J, Haack H, Shen B, Peng C, Li H, Zhou X, Liu X, Rush J, Comb MJ |
PLoS One 2011 Jan 6;6(1):e15640 |
PMID 21253578 |
|
Identification of ROS1 rearrangement in gastric adenocarcinoma |
Lee J, Lee SE, Kang SY, Do IG, Lee S, Ha SY, Cho J, Kang WK, Jang J, Ou SH, Kim KM |
Cancer 2013 May 1;119(9):1627-35 |
PMID 23400546 |
|
Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). |
Ou S, Bang Y, Camidge D, et al. |
ASCO Meeting Abstracts 2013;31:8032 |
|
ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway |
Ou SH, Tan J, Yen Y, Soo RA |
Expert Rev Anticancer Ther 2012 Apr;12(4):447-56 |
PMID 22500682 |
|
Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion |
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H |
Clin Cancer Res 2012 Aug 15;18(16):4449-57 |
PMID 22661537 |
|
RET, ROS1 and ALK fusions in lung cancer |
Takeuchi K, Soda M, Togashi Y, Suzuki R, Sakata S, Hatano S, Asaka R, Hamanaka W, Ninomiya H, Uehara H, Lim Choi Y, Satoh Y, Okumura S, Nakagawa K, Mano H, Ishikawa Y |
Nat Med 2012 Feb 12;18(3):378-81 |
PMID 22327623 |
|
Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer |
Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB |
J Thorac Oncol 2012 Jul;7(7):1086-90 |
PMID 22617245 |
|